Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston — Atlanta, Georgia

Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston is a clinical research site located in Atlanta, Georgia, United States 30329.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston has participated in 1 clinical trials with 1 currently active.

Therapeutic areas: Hemoglobinopathy, Sickle Cell Disease.

Sponsors: Beam Therapeutics Inc..

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston?

Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston conducted?

Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston has 1 clinical trials on record, with 1 currently active. Their work covers Hemoglobinopathy, Sickle Cell Disease.

Is Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston accredited by Crixeo Health?

Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Children's Healthcare of Atlanta - Aflac Cancer and Blood Disorders Center- Egleston?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.